Equities

AstraZeneca PLC

AZN:LSE

AstraZeneca PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)10,062.00
  • Today's Change93.00 / 0.93%
  • Shares traded4.89m
  • 1 Year change-1.28%
  • Beta0.3964
Data delayed at least 20 minutes, as of Nov 21 2024 14:33 GMT.
More ▼

Profile data is unavailable for this security.

About the company

AstraZeneca PLC is a science-led biopharmaceutical company. It discovers, develops, and commercializes prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal and metabolism, respiratory and immunology and vaccines and immune therapies. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex, Faslodex and others. Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its biopharmaceuticals products include Farxiga, Crestor, Breztri and others. Its investigational vaccine candidate IVX-A12, which targets both respiratory syncytial virus and human metapneumovirus. Its oncology candidate includes FPI-2265 targeting prostate specific membrane antigen for metastatic castration resistant prostate cancer, which is in a Phase II trial. It also discovers, develops, and manufactures T-cell receptor therapies. Its Eneboparatide is an investigational therapeutic peptide.

  • Revenue in GBP (TTM)40.48bn
  • Net income in GBP5.13bn
  • Incorporated1992
  • Employees89.90k
  • Location
    AstraZeneca PLC1 Francis Crick AvenueCambridge Biomedical CampusCAMBRIDGE CB2 0AAUnited KingdomGBR
  • Phone+44 20 7304 5000Fax+44 20 7604 8151
  • Websitehttps://www.astrazeneca.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		AZN:LSE since
announced		Transaction
value
Fusion Pharmaceuticals IncDeal completed19 Mar 202419 Mar 2024Deal completed-2.22%2.30bn
Amolyt Pharma SASDeal completed14 Mar 202414 Mar 2024Deal completed-3.79%1.05bn
Gracell Biotechnologies IncDeal completed26 Dec 202326 Dec 2023Deal completed-3.58%1.10bn
Icosavax IncDeal completed12 Dec 202312 Dec 2023Deal completed-0.34%862.87m
Data delayed at least 20 minutes, as of Nov 21 2024 14:33 GMT.

Peer analysis

CompanyRevenue (TTM)Net income (TTM)Market capEmployeesMarket Cap /
Employees
Gilead Sciences, Inc.22.37bn99.59m87.31bn18.00k87.31bn18.00k
Bristol-Myers Squibb Co37.49bn-5.74bn92.79bn34.10k92.79bn34.10k
Sanofi SA40.72bn3.76bn96.02bn87.99k96.02bn87.99k
Pfizer Inc47.51bn3.38bn111.71bn88.00k111.71bn88.00k
Amgen Inc25.72bn3.34bn122.31bn26.70k122.31bn26.70k
AstraZeneca plc40.48bn5.13bn154.94bn89.90k154.94bn89.90k
Novartis AG39.46bn9.29bn178.47bn76.06k178.47bn76.06k
Roche Holding AG52.55bn9.49bn181.73bn103.61k181.73bn103.61k
Merck & Co Inc49.93bn9.60bn194.83bn72.00k194.83bn72.00k
Data as of Nov 21 2024. Currency figures normalised to AstraZeneca PLC's reporting currency: UK Pound GBX

Institutional shareholders

22.35%Per cent of shares held by top holders
HolderShares% Held
BlackRock Investment Management (UK) Ltd.as of 31 Dec 202368.51m4.42%
Wellington Management Co. LLPas of 31 Dec 202365.12m4.20%
The Vanguard Group, Inc.as of 01 Oct 202456.73m3.66%
Norges Bank Investment Managementas of 01 Oct 202432.47m2.10%
BlackRock Fund Advisorsas of 01 Oct 202430.04m1.94%
Capital Research & Management Co. (Global Investors)as of 01 Oct 202423.73m1.53%
Capital International Ltd.as of 01 Oct 202421.90m1.41%
SSgA Funds Management, Inc.as of 01 Oct 202416.75m1.08%
BlackRock Advisors LLCas of 01 Oct 202415.69m1.01%
Legal & General Investment Management Ltd.as of 01 Oct 202415.58m1.01%
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.